ImmunoGen Announces Susan Altschuller on FMLA Leave; Interim CFO Appointed
December 28 2022 - 4:30PM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field
of antibody-drug conjugates (ADCs) for the treatment of cancer,
today announced that Susan Altschuller, PhD, Senior Vice President
and Chief Financial Officer (CFO), is on leave under the Family and
Medical Leave Act (FMLA) and will not continue employment with
ImmunoGen at the conclusion of her leave. Dr. Altschuller’s leave
is unrelated to the Company’s financial or business
performance.
Renee Lentini, Vice President of Finance and Chief Accounting
Officer, has been appointed interim CFO while the Company engages
in a search for Dr. Altschuller’s permanent replacement. Since
joining ImmunoGen in 2004, Ms. Lentini has held positions of
increasing responsibility with the Company’s finance organization,
including oversight for global accounting, tax, and treasury.
“On behalf of the Board of Directors, I thank Susan for her
contributions to the company and wish her the best. We have a
strong finance team in place to support the business and will move
quickly to initiate a search for a new CFO,” said Mark Enyedy,
ImmunoGen’s President and Chief Executive Officer. “With the recent
FDA approval of ELAHERE™ (mirvetuximab soravtansine-gynx) for
platinum-resistant ovarian cancer, our top priority is executing
the US launch with excellence and we look forward to a promising
year ahead as we expand upon a strong start in the market and
advance our pipeline of novel ADCs.”
ABOUT IMMUNOGEN
ImmunoGen is developing the next generation of antibody-drug
conjugates (ADCs) to improve outcomes for cancer patients. By
generating targeted therapies with enhanced anti-tumor activity and
favorable tolerability profiles, we aim to disrupt the progression
of cancer and offer our patients more good days. We call this our
commitment to TARGET A BETTER NOW™.
Learn more about who we are, what we do, and how we do it at
www.immunogen.com.
ABOUT ELAHERE (MIRVETUXIMAB SORAVTANSINE-GYNX)
ELAHERE (mirvetuximab soravtansine-gynx) is a first-in-class ADC
comprising a folate receptor alpha-binding antibody, cleavable
linker, and the maytansinoid payload DM4, a potent tubulin
inhibitor designed to kill the targeted cancer cells. Please see
full Prescribing Information, including a Boxed Warning, for
ELAHERE here.
FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. These
statements include, but are not limited to, ImmunoGen’s
expectations related to the commercial launch of mirvetuximab.
Various factors could cause ImmunoGen’s actual results to differ
materially from those discussed or implied in the forward-looking
statements, and you are cautioned not to place undue reliance on
these forward-looking statements, which are current only as of the
date of this release. Factors that could cause future results to
differ materially from such expectations include, but are not
limited to: the timing and outcome of the Company’s preclinical and
clinical development processes; the difficulties inherent in the
development of novel pharmaceuticals, including uncertainties as to
the timing, expense, and results of preclinical studies, clinical
trials, and regulatory processes; the timing and outcome of the
Company’s anticipated interactions with regulatory authorities,
including that the FDA may determine that our BLA for mirvetuximab
does not meet the conditions for accelerated approval; the risk
that we may not be able to obtain adequate prices and reimbursement
for any approved products, including the potential for delays or
additional difficulties for mirvetuximab; the risk that the results
of the ongoing MIRASOL trial may fail to support full approval of
mirvetuximab and, if so, that additional studies may be required;
risks and uncertainties associated with the scale and duration of
the COVID-19 pandemic and the resulting impact on ImmunoGen’s
industry and business; and other factors as set forth in the
Company’s Annual Report on Form 10-K filed with the Securities and
Exchange Commission on February 28, 2022, Quarterly Reports on Form
10-Q filed with the Securities and Exchange Commission on May 6,
2022, August 1, 2022 and November 4, 2022, and other reports filed
with the Securities and Exchange Commission. The forward-looking
statements in this press release speak only as of the date of this
press release. We undertake no obligation to update any
forward-looking statement, whether as a result of new information,
future developments, or otherwise, except as may be required by
applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221228005248/en/
INVESTOR RELATIONS CONTACT ImmunoGen Anabel Chan
781-895-0600 anabel.chan@immunogen.com
MEDIA CONTACTS ImmunoGen Courtney O’Konek 781-895-0600
courtney.okonek@immunogen.com
OR
FTI Consulting Robert Stanislaro 212-850-5657
robert.stanislaro@fticonsulting.com
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From May 2024 to Jun 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jun 2023 to Jun 2024